A protein called alpha-synuclein builds up into toxic clumps in the brains of people with Parkinson's disease and related conditions. Those clumps damage and kill neurons over time. Current treatments only manage symptoms. They do not stop the clumping. Now, a multinational research team has found that tiny carbon particles called graphene quantum dots may be able to do what existing drugs cannot.
According to a report by Phys.org, the team was led by Professor Małgorzata Kujawska at the Poznań University of Medical Sciences in Poznań, Poland. The researchers published their findings in the journal Science and Technology of Advanced Materials. Their study looked at how graphene quantum dots, known as GQDs, interact with alpha-synuclein to prevent it from forming the long, toxic fibers that are a hallmark of synucleinopathies, a group of diseases that includes Parkinson's and multiple system atrophy.
The research used a multi-stage approach. The team first tested the GQDs in cell-free environments, then in neuronal cultures, and finally in animal models of multiple system atrophy. When the particles were administered intranasally in mice, they significantly reduced the presence of toxic protein aggregates in the brain. The treatment also appeared to activate autophagy, a biological recycling process that helps cells break down and remove damaged proteins.
Safety is a critical question with any nanomaterial intended for medical use. At concentrations relevant to its biological effects, the GQD showed a favorable safety profile. However, some changes in cellular stress and immune responses were observed at higher doses. The researchers noted that many nanomaterials face hurdles in medical applications because of concerns over long-term biocompatibility, and this work is no exception.
Challenges remain before anything like this could reach a clinic. One technical problem is preventing the quantum dots from clumping together in liquid suspensions, which would reduce their effectiveness. The researchers were clear that clinical use is not close.
"This study points to a promising new direction for strategies against neurodegenerative diseases," said Professor Kujawska. "While clinical use of GQDs remains a long way off, these findings strengthen the case for further research."
The broader significance of the work may extend beyond Parkinson's disease. Toxic protein aggregation is a feature of several other neurological conditions as well. The researchers believe that what they learn from optimizing GQDs could eventually inform nanomaterial-based approaches to those diseases too.
"GQDs may serve as a useful research tool," Professor Kujawska said. "What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins."
The study was authored by Tuba Oz and colleagues and carries the DOI 10.1080/14686996.2026.2662693. The research team was multinational, reflecting the scope of international collaboration now focused on nanomaterial approaches to neurodegeneration. Professor Kujawska's lab at Poznań remains at the center of that effort.
